Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hem/Oncology > Multiple Myeloma > Flashcards

Multiple Myeloma Flashcards

1
Q

what is multiple myeloma?

A

malignancy of plasma cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what two places can mm be measured in?

A

plasma or urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the genetic factors implicated with mm?

A
  1. familial clusters of mm
  2. multiple genetic mutations (immunoglobulin gene rearrangements)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

mm may be preceded by?

A

MGUS and smoldering mm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe MGUS

A
  1. presence of monoclonal immunoglobulin in blood (≤3 g/dL)
  2. <10% clonal plasma cells in bone marrow
  3. absence of clinical manifestations of MM (e.g. end-organ damage)
  4. conversion rate of MGUS to MM is 1%/year
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe smoldering mm

A
  1. advanced premalignant stage
  2. monoclonal immunoglobulin in blood (≥3 g/dL)
  3. 10%-60% plasma cells in bone marrow
  4. no clinical manifestations of mm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is a malignant plasma cell involved in unregulated production of a monoclonal antibody?

A

m-protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

mm cells supported by supportive bone marrow microenvironment that promotes further expansion of myeloma clones including:

A

IL-6
VEGF
IGF-1
NK-kB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

is mm typically symptomatic or asymptomatic?

A

symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are signs and symptoms of mm?

A

bone pain
fatigue
infection
neurologic symptoms
polyuria
n/v

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are labs associated with mm?

A

elevated m-protein
elevated SCr
hypercalcemia
low Hb
low albumin
elevated B2-microglobulin
elevated C-reactive protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the main cytogenetic associated with mm?

A

Del (17p)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the acronym associated with mm?

A

CRAB:
hypercalcemia
renal insufficiency
anemia
bone lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

for the staging and prognosis of mm what does the revised international staging system include?

A

serum B2-microglobulin
albumin
LDH
high-risk chromosomal abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

describe stage I values of mm

A

serum β2 -microglobulin <3.5 mcg/mL
serum albumin ≥3.5 g/dL
no high-risk cytogenetics
normal LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe stage II values of mm

A

not stage I or III

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

describe stage III values of mm

A

sSerum β2 -microglobulin ≥5.5 mcg/mL
high-risk cytogenetics [t(4;14), t(14;16), del(17p)] or
Elevated LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

for newly diagnosed patients who can tolerate chemotherapy and are transplant eligible patients primary therapy may be followed by?

A

transplant and
maintenance therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

initiating treatment depends on what?

A

if the patient is experiencing symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

is early conventional treatment benefical in patients with MGUS or smoldering mm?

A

no
but some new agents investigated in high-risk smoldering mm may improve survival and delay progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what does the initial therapy for mm include?

A

dexamethasone
IMiDs
proteasome inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is the frequently used regimen that is considered the standard of care for initial mm therapy?

A

bortezomib
lenalidomide
dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

initial therapy depends on whether the patient is what two things?

A
  1. symptomatic
  2. candidate for autologous HSCT
24
Q

what are the eligibility factors for HSCT?

A

age
renal function
performance status
comorbidites

25
Q

If candidates for autologous HSCT they
generally receive 4-6 months of therapy before hematopoietic stem cell collection and there needs to be enough stem cells for how many transplants?

A

2

26
Q

single agent maintenance therapy consists of what drugs?

A

lenlidomide
bortezomib

27
Q

high-dose dexamethasone is associated with what 3 things?

A
  1. higher risk of infection
  2. CNS toxicity
  3. use caution in elderly patients
28
Q

what are the 3 IMiDs?

A

thalidomide
lenalidomide
pomalidomide

29
Q

what are the 2 MOA’s of IMiDs?

A
  1. decrease production of cytokines and growth factors
  2. may also inhibit NF-kB
30
Q

what are the major side effects/toxicities associated with IMiDs?

A
  1. VTE
  2. severe birth defects and embryo-fetal death (REMS program)
31
Q

what are the 3 proteasome inhibitors?

A

bortezomib (IV)
carflizomib (IV)
ixazomib (PO)

32
Q

what is the main MOA of proteasome inhibitors?

A

inhibit proteasome and NF-kB activation

33
Q

what are the main side effects/toxicities associated with bortezomib?

A
  1. fatigue
  2. GI
  3. neuropathy (less neurotoxicity when administered subQ)
34
Q

what are the main side effects/toxicities associated with carfilzomib?

A
  1. peripheral neuropathy (less than bortezomib)
  2. CV
  3. pulmonary
35
Q

what are the main side effects/toxicities associated with ixazomib?

A
  1. myelosuppression
  2. rash
  3. neuropathy
  4. infections including herpes zoster
  5. GI
  6. cardiac (less than carflizomib)
36
Q

what is the monoclonal antibody that targets CD38?

A

daratumumab

37
Q

what is the chimeric IgG- derived monoclonal antibody that also targets CD38?

A

isatuximab-irfc

38
Q

what is the monoclonal antibody directed against SLAMF7?

A

elotuzumab

39
Q

what is the antibody-drug conjugate targeting B cell maturation (BCMA)?

A

belantamab mafodotin

40
Q

what is the REMS program associated with belantamab mafodotin?

A

ophthalmic exam prior to each dose, patients should use lubricating eye drops while on therapy

41
Q

what is an oral inhibitor of histone deacetylase enzymes?

A

panobinostat

42
Q

what is the side effects/toxicities associated with panobinostat?

A
  1. GI
  2. QTc prolongation
  3. myelosuppression
  4. infection
  5. hepatoxicity
43
Q

what is the first in new class of drugs that inhibits nuclear export of tumor suppressor proteins (TSPs) and Exportin 1 (XPO1)?

A

selinexor

44
Q

what is the side effects/toxicities associated with selinexor?

A
  1. myelosuppression
  2. infection
  3. GI
  4. neurotoxicity
45
Q

in 2021, FDA-approvedwhat drug for the treatment of relapsed or refractory MM?

A

idecabtagene vicleucel

46
Q

what is the lenalidomide/bortezomib/dexamethasone regimen?

A
  1. lenalidomide PO daily x 14 days
  2. bortezomib subcutaneously days 1, 4, 8, and 11
  3. dexamethasone PO daily days 1, 8, and 15Repeat q 21 days
47
Q

what are the bone modifying therapies?

A
  1. Bisphosphonates (zoledronic acid, pamidronate)
  2. Denosumab
48
Q

what are the side effects/toxicities associated with the bone modifiying therapies?

A

osteonecrosis of the jaw (ONJ)

49
Q

does zoledronic acid require dose adjustments for renal impairment?

A

yes, not recommended if CrCl <30 mL/min

50
Q

does pamidronate require dose adjustments for renal impairment?

A

consider a reduced initial dose if renal impairment

51
Q

does denosumab require dose adjustments for renal impairment?

A

no

52
Q

what does the monoclonal antibody denosumab direct towards?

A

RANK-L

53
Q

The combination regimen for the initial treatment of multiple myeloma includes which of the following?
a) Dasatinib, proteosome inhibitor, and immunomodulatory agent
b) Dexamethasone, proteosome inhibitor, and immunomodulatory agent
c) Dasatinib, proteosome inhibitor and cisplatin
d) Doxorubicin, paclitaxel, proteosome inhibitor, and immunomodulatory agent

A

B

54
Q

Multiple myeloma is a malignancy of which of the following?
a) Of T cells only
c) Of Plasma cells (e.g. immunoglobulin-producing B lymphocytes)
c) Characterized by clonal proliferation and accumulation of a monoclonal immunoglobulin secreted from the plasma cell that can be measured in the plasma or urine
d) A and B are correct
e) B and C are correct

A

E

55
Q

Bortezomib can be used for the treatment of multiple myeloma because it is a proteosome inhibitor which leads to inhibition of which of the following?
a) NF-kB
b) BCR-ABL
c) mTOR
d) HER-2

A

A

Hem/Oncology (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions